Acquired idiopathic thrombotic thrombocytopenic purpura: Arguments for an autoimmune disease;Purpura thrombotique thrombocytopénique acquis idiopathique: Une maladie autoimmune à part entière

Presse Medicale

Volumn 35, Issue 12 C2, 2006, Pages 1876-1886

  Coppo, Paul ^a   Veyradier, Agnès ^a   Monge, Matthieu ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CLOPIDOGREL; ESTROGEN; FAS LIGAND; RITUXIMAB; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER; CAPILLARY; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOLYTIC ANEMIA; HUMAN; INFECTION; MULTIPLE ORGAN FAILURE; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; REVIEW; THROMBOCYTE AGGREGATION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 33845502309     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(06)74920-x     Document Type: Review

References (86)

1. Hosler GA, Cusumano AM, Hutchins GM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med. 2003; 127: 834-9.
2. Ridolfi RL, Bell WR. Thrombotic thrombocytopenic purpura. Report of 25 cases and review of the literature. Medicine (Baltimore). 1981; 60: 413-28.
3. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998; 339: 1578-84.
4. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998; 339: 1585-94.
5. Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood. 2005; 106: 11-7.
6. Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell. 1986; 46: 185-90.
7. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med. 1991; 325: 398-403.
8. Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood. 2005; 106: 1932-7.
9. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood. 2001; 98: 1765-72.
10. Coppo P, Bengoufa D, Veyradier A, Wolf M, Bussel A, Millot GA et al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore). 2004; 83: 233-44.
11. Scheiflinger F, Knobl P, Trattner B, Plaimauer B, Mohr G, Dockal M et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood. 2003; 102: 3241-3.
12. Uchida T, Wada H, Mizutani M, Iwashita M, Ishihara H, Shibano T et al. Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura. Blood. 2004; 104: 2081-3.
13. Klaus C, Plaimauer B, Studt JD, Dorner F, Lammle B, Mannucci PM et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood. 2004; 103: 4514-9.
14. Rieger M, Mannucci PM, Kremer Hovinga JA, Herzog A, Gerstenbauer G, Konetschny C et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005; 106: 1262-7.
15. Tsai HM. High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura. Am J Hematol. 2000; 65: 251-5.
16. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004; 103: 4043-9.
17. Coppo P, Wolf M, Veyradier A, Bussel A, Malot S, Millot GA et al. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol. 2006; 132: 66-74.
18. Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake MA et al. ADAMTS13 activity in thrombotic thrombocytopenic purpurahemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003; 102: 60-8.
19. Robson WL, Tsai HM. Thrombotic thrombocytopenic purpura attributable to von Willebrand factor-cleaving protease inhibitor in an 8-year-old boy. Pediatrics. 2002; 109: 322-5.
20. Horton TM, Stone JD, Yee D, Dreyer Z, Moake JL, Mahoney DH. Case series of thrombotic thrombocytopenic purpura in children and adolescents. J Pediatr Hematol Oncol. 2003; 25: 336-9.
21. Schneppenheim R, Budde U, Oyen F, Angerhaus D, Aumann V, Drewke E et al. von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Blood. 2003; 101: 1845-50.
22. Caramaschi P, Riccetti MM, Pasini AF, Savarin T, Biasi D, Todeschini G. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura. Report of three cases and review of the literature. Lupus. 1998; 7: 37-41.
23. Musio F, Bohen EM, Yuan CM, Welch PG. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum. 1998; 28: 1-19.
24. Gungor T, Furlan M, Lammle B, Kuhn F, Seger RA. Acquired deficiency of von Willebrand factor-cleaving protease in a patient suffering from acute systemic lupus erythematosus. Rheumatology. 2001; 40: 940-2.
25. Vaidya S, Abul-ezz S, Lipsmeyer E. Thrombotic thrombocytopenic purpura and systemic lupus erythematosus. Scand J Rheumatol. 2001; 30: 308-10.
26. Devinsky O, Petito CK, Alonso DR. Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol. 1988; 23: 380-4.
27. Jain R, Chartash E, Susin M, Furie R. Systemic lupus erythematosus complicated by thrombotic microangiopathy. Semin Arthritis Rheum. 1994; 24: 173-82.
28. Baldwin DS, Gluck MC, Lowenstein J, Gallo GR. Lupus nephritis. Clinical course as related to morphologic forms and their transitions. Am J Med. 1977; 62: 12-30.
29. Descombes E, Droz D, Drouet L, Grunfeld JP, Lesavre P. Renal vascular lesions in lupus nephritis. Medicine (Baltimore). 1997; 76: 355-68.
30. Daugas E, Nochy D, Huong du LT, Duhaut P, Beaufils H, Caudwell V et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol. 2002; 13: 42-52.
31. Manadan AM, Harris C, Schwartz MM, Block JA. The frequency of thrombotic thrombocytopenic purpura in patients with systemic lupus erythematosus undergoing kidney biopsy. J Rheumatol. 2003; 30: 1227-30.
32. Braun J, Sieper J, Schwarz A, Hiepe F, Lenz T, Keller F et al. Widespread vasculopathy with hemolytic uremic syndrome, perimyocarditis and cystic pancreatitis in a young woman with mixed connective tissue disease. Case report and review of the literature. Rheumatol Int. 1993; 13: 31-6.
33. Appel GB, Pirani CL, D'Agati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol. 1994; 4: 1499-515.
34. Sipek-Dolnicar A, Hojnik M, Bozic B, Vizjak A, Rozman B, Ferluga D. Clinical presentations and vascular histopathology in autopsied patients with systemic lupus erythematosus and anticardiolipin antibodies. Clin Exp Rheumatol. 2002; 20: 335-42.
35. Bridoux F, Vrtovsnik F, Noel C, Saunier P, Mougenot B, Lemaitre V et al. Renal thrombotic microangiopathy in systemic lupus erythematosus: clinical correlations and long-term renal survival. Nephrol Dial Transplant. 1998; 13: 298-304.
36. Brunner HI, Freedman M, Silverman ED. Close relationship between systemic lupus erythematosus and thrombotic thrombocytopenic purpura in childhood. Arthritis Rheum. 1999; 42: 2346-55.
37. Nesher G, Hanna VE, Moore TL, Hersh M, Osborn TG. Thrombotic microangiographic hemolytic anemia in systemic lupus erythematosus. Semin Arthritis Rheum. 1994; 24: 165-72.
38. Vasoo S, Thumboo J, Fong KY. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: disease activity and the use of cytotoxic drugs. Lupus. 2002; 11: 443-50.
39. Mannucci PM, Vanoli M, Forza I, Canciani MT, Scorza R. Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). Haematologica. 2003; 88: 914-8.
40. Dunoyer-Geindre S, de Moerloose P, Galve-de Rochemonteix B, Reber G, Kruithof EK. NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies. Thromb Haemost. 2002; 88: 851-7.
41. Riboldi P, Gerosa M, Raschi E, Testoni C, Meroni PL. Endothelium as a target for antiphospholipid antibodies. Immunobiology. 2003; 207: 29-36.
42. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum. 2002; 46: 1019-27.
43. Montecucco C, Di Lauro M, Bobbio-Pallavicini E, Longhi M, Caporali R, De Gennaro F, Ascari E. Anti-phospholipid antibodies and thrombotic thrombocytopenic purpura. Clin Exp Rheumatol. 1987; 5: 355-8.
44. Trent K, Neustater BR, Lottenberg R. Chronic relapsing thrombotic thrombocytopenic purpura and antiphospholipid antibodies: a report of two cases. Am J Hematol. 1997; 54: 155-9.
45. Amoura Z, Costedoat-Chalumeau N, Veyradier A, Wolf M, Ghillani-Dalbin P, Cacoub P et al. Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome. Arthritis Rheum. 2004; 50: 3260-4.
46. Espinosa G, Bucciarelli S, Cervera R, Lozano M, Reverter JC, de la Red G et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis. 2004; 63: 730-6.
47. Cerveny KC, Sawitzke AD. Relapsing catastrophic antiphospholipid antibody syndrome: a mimic for thrombotic thrombocytopenic purpura? Lupus. 1999; 8: 477-81.
48. Amigo MC, Garcia-Torres R, Robles M, Bochicchio T, Reyes PA. Renal involvement in primary antiphospholipid syndrome. J Rheumatol. 1992; 19: 1181-5.
49. Piette JC, Cacoub P, Wechsler B. Renal manifestations of the antiphospholipid syndrome. Semin Arthritis Rheum. 1994; 23: 357-66.
50. Hughson MD, McCarty GA, Brumback RA. Spectrum of vascular pathology affecting patients with the antiphospholipid syndrome. Hum Pathol. 1995; 26: 716-24.
51. Nochy D, Daugas E, Droz D, Beaufils H, Grunfeld JP, Piette JC et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol. 1999; 10: 507-18.
52. Tandon NN, Rock G, Jamieson GA. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. Br J Haematol. 1994; 88: 816-25.
53. Schultz DR, Arnold PI, Jy W, Valant PA, Gruber J, Ahn YS et al. Anti-CD36 autoantibodies in thrombotic thrombocytopenic purpura and other thrombotic disorders: identification of an 85 kD form of CD36 as a target antigen. Br J Haematol. 1998; 103: 849-57.
54. Xie L, Chesterman CN, Hogg PJ. Control of von Willebrand factor multimer size by thrombospondin-1. J Exp Med. 2001; 193: 1341-9.
55. Rock G, Clark W, Sternbach M, Kolajova M, McLaine P. Haemolytic uraemic syndrome is an immune-mediated disease: role of anti-CD36 antibodies. Br J Haematol. 2005; 131: 247-52.
56. Henon P. Traitement du purpura thrombotique thrombopénique. Résultats d'une étude clinique multicentrique randomisée. Presse Med. 1991; 20: 1761-7.
57. Studt JD, Hovinga JA, Radonic R, Gasparovic V, Ivanovic D, Merkler M et al. Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins. Blood. 2004; 103: 4195-7.
58. Joseph G, Smith KJ, Hadley TJ, Djulbegovic B, Troup GM, Oldfather J et al. HLA-DR53 protects against thrombotic thrombocytopenic purpura/adult hemolytic uremic syndrome. Am J Hematol. 1994; 47: 189-93.
59. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med. 1998; 128: 541-4.
60. Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000; 342: 1773-7.
61. Mauro M, Zlatopolskiy A, Raife TJ, Laurence J. Thienopyridine-linked thrombotic microangiopathy: association with endothelial cell apoptosis and activation of MAP kinase signalling cascades. Br J Haematol. 2004; 124: 200-210.
62. Travers RL, Hughes GR. Oral contraceptive therapy and systemic lupus erythematosus. J Rheumatol. 1978; 5: 448-51.
63. Ruiz-Irastorza G, Lima F, Alves J, Khamashta MA, Simpson J, Hughes GR et al. Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies. Br J Rheumatol. 1996; 35: 133-8.
64. Grimaldi CM, Michael DJ, Diamond B. Cutting edge: expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. J Immunol. 2001; 167: 1886-90.
65. Grimaldi CM, Cleary J, Dagtas AS, Moussai D, Diamond B. Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest. 2002; 109: 1625-33.
66. Bynoe MS, Grimaldi CM, Diamond B. Estrogen up-regulates Bcl-2 and blocks tolerance induction of naive B cells. Proc Natl Acad Sci. 2000; 97: 2703-8.
67. 17beta-estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells. Blood. 2004; 104: 1404-10.
68. Moro L, Reineri S, Piranda D, Pietrapiana D, Lova P, Bertoni A et al. Nongenomic effects of 17beta-estradiol in human platelets: potentiation of thrombin-induced aggregation through estrogen receptor beta and Src kinase. Blood. 2005; 105: 115-21.
69. Fontana S, Gerritsen HE, Kremer Hovinga J, Furlan M, Lammle B. Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease. Br J Haematol. 2001; 113: 100-2.
70. Tomer Y, Sherer Y, Shoenfeld Y. Autoantibodies, autoimmunity and cancer (review). Oncol Rep. 1998; 5: 753-61.
71. Abu-Shakra M, Buskila D, Ehrenfeld M, Conrad K, Shoenfeld Y. Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis. 2001; 60: 433-41.
72. Gerritsen ME, Bloor CM. Endothelial cell gene expression in response to injury. Faseb J. 1993; 7: 523-32.
73. Chi L, Li Y, Stehno-Bittel L, Gao J, Morrison DC, Stechschulte DJ, Dileepan KN. Interleukin-6 production by endothelial cells via stimulation of protease-activated receptors is amplified by endotoxin and tumor necrosis factor-alpha. J Interferon Cytokine Res. 2001; 21: 231-40.
74. Jersmann HP, Hii CS, Ferrante JV, Ferrante A. Bacterial lipopolysaccharide and tumor necrosis factor alpha synergistically increase expression of human endothelial adhesion molecules through activation of NF-kappaB and p38 mitogen-activated protein kinase signaling pathways. Infect Immun. 2001; 69: 1273-9.
75. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation. 2002; 105: 816-22.
76. Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest. 2004; 113: 1641-50.
77. Motto DG, Chauhan AK, Zhu G, Homeister J, Lamb CB, Desch KC et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest. 2005; 115: 2752-61.
78. Becker S, Fusco G, Fusco J, Balu R, Gangjee S, Brennan C et al. HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis. 2004; 39: S267-75.
79. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000; 408: 740-5.
80. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci. 2001; 98: 9237-42.
81. Krieg AM. A role for Toll in autoimmunity. Nat Immunol. 2002; 3: 423-4.
82. Waldner H, Collins M, Kuchroo VK. Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. J Clin Invest. 2004; 113: 990-7.
83. Mitra D, Jaffe EA, Weksler B, Hajjar KA, Soderland C, Laurence J. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood. 1997; 89: 1224-34.
84. Dang CT, Magid MS, Weksler B, Chadburn A, Laurence J. Enhanced endothelial cell apoptosis in splenic tissues of patients with thrombotic thrombocytopenic purpura. Blood. 1999; 93: 1264-70.
85. Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum. 1997; 40: 1126-9.
86. Hamzaoui K, Hamzaoui A, Zakraoui L, Chabbou A. Levels of soluble Fas/APO-1 in patients with Behcet's disease. Mediators Inflamm. 1998; 7: 111-4.